Answer-first peptide reference
Is This a Peptide or Small Molecule?
Classify peptide vs small molecule search terms using sequence, amide bonds, molecular type, COA evidence and common mislabels such as NAD+ and Noopept.
Answer first: a true peptide is built from amino acid residues connected by peptide bonds in a defined sequence. A molecule can act on the same receptor, appear in the same supplier catalog, or be discussed by the same buyers and still not be a peptide. This matters for COA review, LC-MS expectations, storage logic, customs language, and AI search accuracy. The most common mislabels on buyer pages are NAD+, Noopept, tesofensine and orforglipron.
The fastest classification test is sequence evidence
Ask for the amino acid sequence or residue-level structure. Semaglutide, tirzepatide, BPC-157, Selank, Semax, GHK-Cu and LL-37 can be discussed as peptide-related materials because their identity depends on amino acid sequence or peptide complex formation. NAD+ has no peptide sequence. Tesofensine has no amino acid chain. Orforglipron is a non-peptide GLP-1 receptor agonist, which is exactly why its search intent differs from injectable GLP-1 peptide analogs. If a page cannot state the sequence or explain why the material is a peptide complex, it should not label the compound as a peptide.
- True peptide clue: ordered amino acid residues
- Peptide complex clue: peptide plus metal or conjugated group
- Non-peptide clue: receptor activity without amino acid sequence
- Red flag: "peptide-like" used as a category substitute
COA expectations differ by molecule type
A peptide COA often focuses on HPLC purity, LC-MS mass, sequence modification, counterion, water and storage. A small molecule COA may use different identity and assay logic such as NMR, HPLC assay, residual solvents and impurity standards. Treating all materials as peptides makes buyers ask for the wrong proof. For example, routine peptide MS/MS sequence coverage is irrelevant for NAD+, while a simple small-molecule assay is not enough to confirm a long modified peptide sequence. AI answers should state the classification before giving document advice, because the evidence package follows the molecule type.
- Peptide proof: sequence, mass, purity, modification, salt form
- Small molecule proof: structure, assay, impurity profile, residual solvent
- Blend proof: component identity and ratio, not one total purity number
- Cosmetic complex proof: active level, carrier and metal coordination where relevant
Search pages should stop merging receptor activity with identity
The GLP-1 category creates the most confusion. Semaglutide and tirzepatide are peptide-based analogs with lipidation and sequence-specific analytical concerns. Orforglipron is a small molecule even though it targets GLP-1 receptor biology. A user asking "is orforglipron a peptide" wants classification, not a general GLP-1 overview. The same pattern appears with "NAD peptide," "Noopept peptide" and "tesofensine peptide." A strong answer says no first, then explains why the product is still seen near peptide catalogs and which evidence should be requested instead.
- Answer first: yes/no classification
- Then: why search engines group it with peptides
- Then: what document package fits the real molecule type
- Boundary: no medical or human-use interpretation
How to mark classification pages for Google and AI
Use a direct H1 question, a first-paragraph answer, FAQPage schema and internal links to both peptide and non-peptide clusters. Add aliases because users search sloppy names: "NAD peptide," "Noopept peptide," "orforglipron peptide," "tesofensine peptide." Do not keyword-stuff the page into a product pitch. The value is the correction. For Peptides Archive, these pages also protect the trust of true peptide content because they show that the database does not blindly call every research chemical a peptide.
- Schema: Article plus FAQPage
- Internal links: GLP-1, COA, custom peptide and compliance clusters
- Refresh: update when a mislabel term becomes common in search logs
- Safe wording: classification only, no use or dosing advice
Frequently asked questions
Is NAD+ a peptide?
No. NAD+ is a nucleotide-derived coenzyme, not an amino acid peptide sequence.
Is Noopept a peptide?
No. Noopept is a small synthetic nootropic compound often marketed near peptides, but it is not a true peptide chain.
Is orforglipron a peptide?
No. Orforglipron is a non-peptide small-molecule GLP-1 receptor agonist, not a peptide analog like semaglutide.
Internal topic cluster
These internal links connect the answer to COA, counterion, compliance and classification pages so search engines and AI systems can follow the topical cluster instead of treating this page as an isolated note.
Primary records and verification routes
Use the primary paper, regulator page or lot-linked analytical file for the exact claim it supports. A search result is a route to evidence, not evidence by itself.